Drug intelligence / Profile preview

AERx insulin

Development stage: Discontinued
Lead developer: Novo Nordisk
Modality: Recombinant Proteins and Enzymes
Administration: Inhalation

Overview

AERx insulin is an inhaled liquid formulation of regular human insulin delivered via the AERx insulin Diabetes Management System (AERx iDMS). Developed through a collaboration between Aradigm Corporation and Novo Nordisk, the system utilizes a proprietary nozzle technology to create a fine aerosol of liquid droplets (1-3 μm) for deep lung delivery and systemic absorption. This delivery method provides a rapid onset of action, mimicking the pharmacokinetic profile of fast-acting insulin analogs. The drug targets the insulin receptor to regulate glucose metabolism in patients with type 1 and type 2 diabetes mellitus. Although it reached Phase III clinical trials, development was discontinued by Novo Nordisk in 2008.

Other names: AERx iDMS insulininhaled liquid insulin

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on AERx insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AERx insulin.